Clinical Trials Browser

Completed × Ovarian Neoplasms × Imatinib Mesylate × Clear all

Ovarian Neoplasms

NCT00039585 2015-04-30

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Phase 2 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00510653 2013-08-23

Gleevec Study for Patients With Ovarian Cancer

Phase 2 Completed

73 enrolled 4 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00006357 2012-09-24

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Phase 1/2 Completed

91 enrolled

GastrointestinalGynecologicSarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Ovarian Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Endometrial Neoplasms, Sarcoma, Endometrial Stromal, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Gastrointestinal Stromal Tumors, Histiocytoma, Malignant Fibrous

Clinical Trials

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Gleevec Study for Patients With Ovarian Cancer

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma